2m 2m 2m 2m 2m 2m 2m
Panacea Life Sci (PLSH)
OTC
$0.04$0.00 (0.00%)
Price as of Jun 02, 2026- $742,832.00Market Cap
- -6.29%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Panacea Life Sci (PLSH)
$0.04$0.00 (0.00%)
Annual
Quarterly
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 2.4M +46.59% | 1.6M -21.01% | 2.1M -0.55% | 2.1M N/A | |
Cost of Revenue | 1.3M +2.64% | 1.2M -18.99% | 1.5M -34.01% | 2.3M N/A | |
Gross Profit | 1.1M +182.99% | 396,470 -26.66% | 540,578 +183.34% | -648,616 N/A | |
Sales and Marketing Expense | 17,947 -91.42% | 209,254 -44.63% | 377,916 -40.82% | 638,632 N/A | |
Research and Development Expense | N/A N/A | N/A N/A | N/A N/A | 0 N/A | |
Depreciation and Amortization Expense | 1.7M +2,689.81% | 61,401 +0.002% | 61,400 -91.64% | 734,584 N/A | |
Total Operating Expenses | 6.7M +10.24% | 6.0M -6.62% | 6.5M -34.61% | 9.9M N/A | |
Operating Profit | -5.5M -1.88% | -5.7M -4.80% | -5.9M -43.75% | -10.6M N/A | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -1.6M -24.04% | -2.0M +85.31% | -1.1M +10.15% | -1.0M N/A | |
Interest Income and Expense and Net | -1.6M -24.04% | -2.0M +85.31% | -1.1M +10.15% | -1.0M N/A | |
Total Nonoperating Income and Expense | -2.5M -29.26% | -3.5M -402.25% | 1.2M +398.74% | -386,543 N/A | |
Income before Taxes | -8.0M -12.33% | -9.1M +91.17% | -4.8M -56.29% | -10.9M N/A | |
Income Taxes | N/A N/A | N/A N/A | N/A N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | 4.6M N/A | |
Net Income | -8.0M -12.33% | -9.1M +91.17% | -4.8M -56.29% | -10.9M N/A | |
Net Income from Continuing Operations Applicable to Common | -8.0M -12.33% | -9.1M +91.17% | -4.8M -49.45% | -9.5M N/A | |
Basic EPS and Net Income | -0.48 -22.58% | -0.62 +129.63% | -0.27 +22.73% | -0.22 N/A | |
Diluted EPS and Net Income | -0.48 -22.58% | -0.62 +129.63% | -0.27 +22.73% | -0.22 N/A | |
Basic Weighted Average Shares | 16.6M +11.88% | 14.9M -16.60% | 17.8M -64.14% | 49.7M N/A | |
Diluted Weighted Average Shares | 16.6M +11.88% | 14.9M -16.60% | 17.8M -64.14% | 49.7M N/A | |
Balance Sheet | |||||
Cash and Cash Equivalents | 100,922 +1,351.91% | 6,951 -64.85% | 19,774 -21.34% | 25,139 N/A | |
Short-Term Investments | 14,933 -98.65% | 1.1M -70.79% | 3.8M N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 115,855 -89.60% | 1.1M -70.76% | 3.8M +15,060.73% | 25,139 N/A | |
Total Current Assets | 4.7M -27.04% | 6.4M -29.85% | 9.1M +17,701.87% | 51,109 N/A | |
Accumulated Depreciation | 7.2M +31.02% | 5.5M +42.99% | 3.9M +2,492.10% | 149,003 N/A | |
Property and Plant and Equipment and Net | 6.4M -16.00% | 7.7M -13.17% | 8.8M +43,751.29% | 20,159 N/A | |
Total Long-Term Assets | 6.4M -16.00% | 7.7M -13.17% | 8.8M +43,751.29% | 20,159 N/A | |
Total Assets | 18.0M -7.73% | 19.5M -18.06% | 23.8M +33,272.13% | 71,268 N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 25.0M +144.86% | 10.2M +53.39% | 6.7M +607.09% | 942,147 N/A | |
Total Current Liabilities | 19.4M +29.02% | 15.1M +49.68% | 10.1M +105.33% | 4.9M N/A | |
Total Long-Term Debt | 115,000 -95.62% | 2.6M -67.60% | 8.1M +3,847.58% | 205,166 N/A | |
Total Long-Term Liabilities | 3.6M +19.61% | 3.0M -10.76% | 3.3M +1,531.53% | 205,166 N/A | |
Total Liabilities | 26.3M +21.45% | 21.6M +29.69% | 16.7M +226.44% | 5.1M N/A | |
Retained Earnings | -33.9M +30.94% | -25.9M +54.53% | -16.8M -44.82% | -30.4M N/A | |
Total Stockholders Equity | -8.3M +286.63% | -2.1M -130.19% | 7.1M +317.98% | -3.3M N/A | |
Total Shares Outstanding | 17.6M +17.91% | 15.0M +6.34% | 14.1M -75.03% | 56.4M N/A | |
Cash Flow | |||||
Cash from Operating Activities | -1.5M -36.47% | -2.4M -38.82% | -3.9M +460.55% | -699,686 N/A | |
Capital Expenditures | 65,322 -73.21% | 243,804 +49.62% | 162,946 N/A | 0 N/A | |
Cash from Investing Activities | -65,322 -66.84% | -196,972 -137.70% | 522,533 N/A | 0 N/A | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 1.7M -34.83% | 2.6M -22.53% | 3.3M +372.09% | 706,420 N/A | |
Financials Ratio | |||||
Gross Margin | 47.04% +93.05% | 24.37% -7.15% | 26.25% +335.48% | -11.15% N/A | |
Operating Margin | -232.55% -33.06% | -347.41% +20.52% | -288.26% -43.44% | -509.65% N/A | |
Return on Assets | -42.78% +1.24% | -42.26% +5.39% | -40.10% -81.91% | -221.70% N/A | |
Return on Equity | 153.61% +141.65% | -368.81% +48.23% | -248.82% -89.07% | -2,277.04% N/A | |
Revenue Growth | 46.59% +321.78% | -21.01% +3,722.09% | -0.55% -100.11% | 499.11% N/A | |
Current Ratio | 0.24 -43.46% | 0.42 -53.13% | 0.90 +8,586.54% | 0.01 N/A | |
Cash Ratio | 0.005 +940.00% | 0.0005 -75.00% | 0.002 -60.78% | 0.005 N/A | |
Debt-to-Equity Ratio | -3.03 -49.38% | -5.99 -388.14% | 2.08 +690.26% | -0.35 N/A | |
Debt-to-Assets Ratio | 1.40 +112.13% | 0.66 +6.17% | 0.62 -96.15% | 16.10 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow